Diabetes and hypertension are expected to drive the global prevalence of CKD, with much of this increasing burden observed in Asian locations of China and India.
一家致力於推進新藥開發進程的國際性受託研究機構 (CRO) 和科學諮詢合作夥伴
立足臨床試驗,護航人類健康未來。
協同合作共進,科創驅動前行。
深耕產業標竿,鑄就卓越口碑。
深耕臨床科研數十載,引領產業發展標竿。
Diabetes and hypertension are expected to drive the global prevalence of CKD, with much of this increasing burden observed in Asian locations of China and India.